Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 5 | 2022 | 1668 | 1.490 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2021 | 264 | 1.280 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 1076 | 0.820 |
Why?
|
| Troponin | 3 | 2022 | 524 | 0.760 |
Why?
|
| Parental Leave | 1 | 2021 | 79 | 0.760 |
Why?
|
| Hypotension, Orthostatic | 1 | 2022 | 255 | 0.680 |
Why?
|
| Adrenocortical Adenoma | 1 | 2018 | 48 | 0.630 |
Why?
|
| Awards and Prizes | 1 | 2022 | 375 | 0.610 |
Why?
|
| Policy Making | 1 | 2021 | 554 | 0.600 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 371 | 0.590 |
Why?
|
| Anthracyclines | 1 | 2019 | 288 | 0.580 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2016 | 42 | 0.570 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2018 | 162 | 0.570 |
Why?
|
| Pacemaker, Artificial | 1 | 2022 | 816 | 0.550 |
Why?
|
| Reimbursement Mechanisms | 1 | 2021 | 670 | 0.540 |
Why?
|
| Hyperaldosteronism | 1 | 2018 | 240 | 0.510 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 692 | 0.510 |
Why?
|
| Fluorouracil | 1 | 2019 | 1619 | 0.500 |
Why?
|
| Physicians, Women | 1 | 2019 | 486 | 0.460 |
Why?
|
| Aldosterone | 1 | 2018 | 877 | 0.450 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 1265 | 0.440 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 462 | 0.420 |
Why?
|
| Clinical Clerkship | 1 | 2018 | 532 | 0.420 |
Why?
|
| Telemedicine | 2 | 2019 | 2872 | 0.410 |
Why?
|
| Aspirin | 2 | 2020 | 3282 | 0.370 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 3068 | 0.350 |
Why?
|
| Referral and Consultation | 2 | 2020 | 3528 | 0.350 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 15165 | 0.340 |
Why?
|
| Hypertension | 3 | 2022 | 8480 | 0.310 |
Why?
|
| Heart Diseases | 1 | 2021 | 2788 | 0.310 |
Why?
|
| Insurance, Health | 1 | 2019 | 2494 | 0.280 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2737 | 0.280 |
Why?
|
| Medicare | 2 | 2021 | 6566 | 0.280 |
Why?
|
| Students, Medical | 1 | 2018 | 1862 | 0.250 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4560 | 0.240 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 2133 | 0.240 |
Why?
|
| Antihypertensive Agents | 3 | 2022 | 2046 | 0.240 |
Why?
|
| Pain | 1 | 2018 | 4986 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2018 | 4687 | 0.210 |
Why?
|
| Sex Factors | 3 | 2021 | 10397 | 0.210 |
Why?
|
| Kidney | 1 | 2016 | 7186 | 0.190 |
Why?
|
| Embolectomy | 1 | 2020 | 120 | 0.170 |
Why?
|
| Humans | 29 | 2022 | 744343 | 0.160 |
Why?
|
| Glucosides | 1 | 2021 | 451 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 20129 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 867 | 0.140 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 11727 | 0.130 |
Why?
|
| Skin Aging | 1 | 2016 | 127 | 0.130 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 845 | 0.130 |
Why?
|
| Rosacea | 1 | 2015 | 49 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2019 | 2297 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.120 |
Why?
|
| Ultraviolet Rays | 2 | 2016 | 1060 | 0.120 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 818 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2022 | 23338 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21746 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2016 | 591 | 0.110 |
Why?
|
| United States | 7 | 2022 | 69872 | 0.110 |
Why?
|
| Heart Valve Prosthesis | 1 | 2022 | 1488 | 0.110 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 1440 | 0.110 |
Why?
|
| Male | 12 | 2022 | 350118 | 0.110 |
Why?
|
| Myocytes, Cardiac | 1 | 2021 | 1637 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 2 | 2022 | 2337 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2022 | 1922 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2019 | 1167 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2021 | 77449 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 2161 | 0.090 |
Why?
|
| Female | 12 | 2022 | 380194 | 0.090 |
Why?
|
| Patient Readmission | 2 | 2021 | 3114 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 21683 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2022 | 8554 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2021 | 2149 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 25043 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1797 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2018 | 2682 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1354 | 0.080 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 1965 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2018 | 1008 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2020 | 2531 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2021 | 8324 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2021 | 5007 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2020 | 3461 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2019 | 1901 | 0.080 |
Why?
|
| Heart Failure | 2 | 2022 | 10900 | 0.080 |
Why?
|
| Aged | 9 | 2022 | 163280 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 1855 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 2376 | 0.070 |
Why?
|
| Health Promotion | 1 | 2019 | 2205 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2021 | 7729 | 0.070 |
Why?
|
| Medicaid | 1 | 2019 | 2736 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5317 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6489 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2022 | 1683 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12959 | 0.060 |
Why?
|
| Curriculum | 1 | 2018 | 3605 | 0.060 |
Why?
|
| Middle Aged | 9 | 2022 | 213383 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7913 | 0.060 |
Why?
|
| Skin | 1 | 2016 | 4364 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 19905 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 15076 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 57776 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7659 | 0.050 |
Why?
|
| Pregnancy | 1 | 2022 | 29144 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9438 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 322 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 5391 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 29063 | 0.040 |
Why?
|
| Adult | 5 | 2019 | 214055 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 72290 | 0.040 |
Why?
|
| American Heart Association | 1 | 2022 | 1056 | 0.040 |
Why?
|
| Markov Chains | 1 | 2021 | 969 | 0.040 |
Why?
|
| Vena Cava Filters | 1 | 2020 | 252 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2016 | 128 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 5686 | 0.030 |
Why?
|
| Morbidity | 1 | 2022 | 1769 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12261 | 0.030 |
Why?
|
| Chest Pain | 1 | 2022 | 1114 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 565 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 581 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 855 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2020 | 1530 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 453 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 841 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 1573 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1239 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 1475 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 63114 | 0.020 |
Why?
|
| Cause of Death | 1 | 2020 | 3584 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2715 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4751 | 0.020 |
Why?
|
| Phenotype | 2 | 2016 | 16365 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2020 | 3821 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2020 | 5097 | 0.020 |
Why?
|
| Echocardiography | 1 | 2020 | 5102 | 0.020 |
Why?
|
| Survival Rate | 1 | 2022 | 12788 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 168757 | 0.020 |
Why?
|
| Length of Stay | 1 | 2020 | 6309 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 3923 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3158 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2016 | 6459 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2020 | 9146 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13408 | 0.020 |
Why?
|
| Prevalence | 1 | 2021 | 15226 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 15540 | 0.010 |
Why?
|
| Alleles | 1 | 2015 | 6933 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7181 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 20947 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 11366 | 0.010 |
Why?
|
| Genotype | 1 | 2015 | 12951 | 0.010 |
Why?
|
| Young Adult | 2 | 2016 | 56430 | 0.010 |
Why?
|
| Smoking | 1 | 2016 | 8987 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40561 | 0.010 |
Why?
|
| Adolescent | 2 | 2016 | 85781 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2016 | 12208 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12072 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 15519 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10638 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17446 | 0.010 |
Why?
|
Concepts
(159)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(52)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_